Adavosertib
- Generic Name
- Adavosertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32N8O2
- CAS Number
- 955365-80-7
- Unique Ingredient Identifier
- K2T6HJX3I3
- Background
MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 208
- Registration Number
- NCT01827384
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-05-20
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 136
- Registration Number
- NCT01357161
A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 7
- Registration Number
- NCT01076400
A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 206
- Registration Number
- NCT00648648
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath